EAM
TTPH

EverPoint Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

EverPoint Asset Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,000
Closed -$2.93M – 637
2015
Q1 		$2.93M Buy
+4,000
New +$3M 0.06% 371

Other funds holding TTPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EverPoint Asset Management's TTPH Position: Q2 2015 in Review

EverPoint Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2015, closing a stake of 4,000 shares — an estimated $2.93M sold.

EverPoint Asset Management first reported a position in TTPH in Q1 2015 and held it in 1 quarter. The position peaked at $2.93M in Q1 2015. 139 funds tracked by Wall St. Rank hold TTPH as of Q2 2015.

  • EverPoint Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 4,000 Tetraphase Pharmaceuticals, Inc. shares in Q2 2015, an estimated $2.93M.
  • EverPoint Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • EverPoint Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $2.93M in Q1 2015.
  • 139 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2015.

Based on EverPoint Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.